CN112168736A - Whitening and freckle removing composition and preparation method thereof - Google Patents
Whitening and freckle removing composition and preparation method thereof Download PDFInfo
- Publication number
- CN112168736A CN112168736A CN202011100095.6A CN202011100095A CN112168736A CN 112168736 A CN112168736 A CN 112168736A CN 202011100095 A CN202011100095 A CN 202011100095A CN 112168736 A CN112168736 A CN 112168736A
- Authority
- CN
- China
- Prior art keywords
- parts
- solution
- whitening
- melanin
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 208000003351 Melanosis Diseases 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 33
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims abstract description 27
- 150000001413 amino acids Chemical class 0.000 claims abstract description 22
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 18
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 claims abstract description 15
- 229940093767 glabridin Drugs 0.000 claims abstract description 15
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 claims abstract description 15
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 102000008186 Collagen Human genes 0.000 claims abstract description 13
- 108010035532 Collagen Proteins 0.000 claims abstract description 13
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims abstract description 13
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims abstract description 13
- 229920002079 Ellagic acid Polymers 0.000 claims abstract description 13
- 229920001436 collagen Polymers 0.000 claims abstract description 13
- 229960002852 ellagic acid Drugs 0.000 claims abstract description 13
- 235000004132 ellagic acid Nutrition 0.000 claims abstract description 13
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000230 xanthan gum Substances 0.000 claims abstract description 13
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 13
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 13
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 13
- 241000208422 Rhododendron Species 0.000 claims abstract description 12
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 102000011782 Keratins Human genes 0.000 claims abstract description 11
- 108010076876 Keratins Proteins 0.000 claims abstract description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 11
- 229920001184 polypeptide Polymers 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 11
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 11
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 11
- 240000007651 Rubus glaucus Species 0.000 claims abstract description 10
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 10
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 10
- 241000235342 Saccharomycetes Species 0.000 claims abstract description 10
- 229930191209 mulberroside Natural products 0.000 claims abstract description 10
- GLKNXRRXEUBUPQ-UBLSLQRZSA-N mulberroside B Natural products OC[C@H]1O[C@@H](Oc2c(O)cc3OC(=O)C=Cc3c2O)[C@H](O)[C@@H](O)[C@@H]1O GLKNXRRXEUBUPQ-UBLSLQRZSA-N 0.000 claims abstract description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- LNOPAJNGRAPFKZ-UHFFFAOYSA-N 1-benzyl-3-cyclohexyl-1-(piperidin-4-ylmethyl)urea Chemical compound C1CNCCC1CN(CC=1C=CC=CC=1)C(=O)NC1CCCCC1 LNOPAJNGRAPFKZ-UHFFFAOYSA-N 0.000 claims description 7
- XTHRTBCPBWJYRO-UHFFFAOYSA-N 2,3-bis(2-methoxyphenyl)-n-phenyl-1,2,4-thiadiazol-5-imine Chemical compound COC1=CC=CC=C1C(N(S1)C=2C(=CC=CC=2)OC)=NC1=NC1=CC=CC=C1 XTHRTBCPBWJYRO-UHFFFAOYSA-N 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- CSYFFQVEQXEIAB-UHFFFAOYSA-N 4-[(1,4-dioxo-2-naphthalenyl)amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=CC(=O)C2=CC=CC=C2C1=O CSYFFQVEQXEIAB-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 claims description 3
- 240000000249 Morus alba Species 0.000 claims description 2
- 235000008708 Morus alba Nutrition 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 58
- 210000003491 skin Anatomy 0.000 abstract description 25
- 210000004027 cell Anatomy 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 206010014970 Ephelides Diseases 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 210000000434 stratum corneum Anatomy 0.000 abstract description 2
- 239000000758 substrate Substances 0.000 abstract description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 38
- 230000000694 effects Effects 0.000 description 22
- 239000000047 product Substances 0.000 description 18
- 102000003425 Tyrosinase Human genes 0.000 description 15
- 108060008724 Tyrosinase Proteins 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 210000002752 melanocyte Anatomy 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000002156 mixing Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000008099 melanin synthesis Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000012641 Pigmentation disease Diseases 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 230000019612 pigmentation Effects 0.000 description 6
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 5
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000001120 cytoprotective effect Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 102000030612 Melanocortin 5 receptor Human genes 0.000 description 3
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 3
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- -1 stilbene compound Chemical class 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 2
- 101100523286 Coturnix japonica QNR-71 gene Proteins 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 229940124200 Melanin inhibitor Drugs 0.000 description 1
- 101100262328 Mus musculus Dct gene Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- NNQSGBRGJHSRFN-UHFFFAOYSA-N isoflavan Chemical compound C1OC2=CC=CC=C2CC1C1=CC=CC=C1 NNQSGBRGJHSRFN-UHFFFAOYSA-N 0.000 description 1
- 235000002324 isoflavanes Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Abstract
The invention belongs to the technical field of whitening skin care products, has the functions of whitening and removing freckles, and particularly relates to a whitening and freckles removing composition and a preparation method thereof. The composition comprises, by weight, 3290.001-0.01 part of ML, JNJ-102295700.001-0.01 part of JNJ-102295700.001, 26-0.01 part of SRI-0113810.001, 20-40 parts of glycerol, 30-50 parts of sodium hyaluronate solution, 18-23 parts of azalea acid solution, 26-32 parts of ellagic acid solution, 4-4.2 parts of glabridin solution, 20-25 parts of taxifolin solution, 25-32 parts of mulberroside solution, 14-18 parts of raspberry extract solution, 4-6.5 parts of sodium carbonate solution, 3-5 parts of keratin amino acid solution, 3-5 parts of collagen amino acid, 3-5 parts of saccharomycete polypeptide, 4.2-4.6 parts of xanthan gum and 95-105 parts of water. The effective components in the composition compete with the original substrate capable of forming melanin, so that the biosynthesis pathway of the melanin is broken, the aim of inhibiting the melanin is fulfilled, and the cell renewal and metabolism of the melanin are accelerated. The active ingredients of the composition can also activate capillary network, convey and clean deposited melanin, improve cell protection capability, activate skin stem cells and well repair stratum corneum cells damaged by ultraviolet rays.
Description
Technical Field
The invention belongs to the technical field of whitening skin care products, has the functions of whitening and removing freckles, and particularly relates to a whitening and freckles removing composition and a preparation method thereof.
Background
With the improvement of living standard, the requirements and demands of consumers for daily skin care products are gradually increased. The whitening requirement is common to most Asian women, and the concept of the traditional expression of 'one white covering three ugs' is also deep. In recent years, the functions of whitening and freckle-removing cosmetics are gradually improved, from the pursuit of whitening products with a shielding effect, such as powder, whitening powder and honey, in the 80 th of the 20 th century to natural, natural and healthy skin with uniform and white and pure skin in the 90 th of the 20 th century, the pursuit of modern whitening products is started by adding whitening active ingredients, the generation of melanin is inhibited, the biosynthesis process of the melanin is prevented, and therefore the skin is whitened, facial freckles are reduced, and the skin tone is more uniform.
Melanin is produced from small organ melanosomes in pigment cells in the basal layer of the epidermis, then migrates to epidermal cells, enters the stratum corneum while decomposing in the epidermal cells, and finally disappears from the skin together with exfoliated fragments of the keratinocytes. Melanin functions to protect the body from uv light, and excess and uneven aggregation of melanin are responsible for the formation of skin blackness and spots. The mechanism of melanin production is believed to be tyrosine-catalyzed synthesis of melanosomes in melanocytes. The oxidation of tyrosine to melanin is complex and ultraviolet light causes the enhancement of tyrosinase activity and melanocyte activity, thereby promoting the oxidation and further deepening or even worsening the original pigmentation. Based on the above principle, if a skin care product for whitening and removing freckles can be developed, the skin care product can not only inhibit the formation of melanin, but also reduce the deposition of melanin, accelerate the renewal and metabolism of melanocytes, and improve the cytoprotective ability, and the skin care product becomes an urgent need for many beauty-conscious people.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a whitening and freckle-removing composition capable of inhibiting the formation of melanin, reducing the deposition of the melanin, accelerating the renewal and metabolism of melanocytes and improving the cytoprotective ability and a preparation method thereof.
In order to achieve the purpose, the invention adopts the technical scheme that:
a whitening and freckle-removing composition comprises, by weight, ML 3290.001-0.01 part, JNJ-102295700.001-0.01 part, SRI-0113810.001-0.01 part, glycerol 20-40 parts, sodium hyaluronate liquid 30-50 parts, azalea acid liquid 18-23 parts, ellagic acid liquid 26-32 parts, glabridin liquid 4-4.2 parts, taxifolin liquid 20-25 parts, mulberroside liquid 25-32 parts, raspberry extract liquid 14-18 parts, sodium carbonate liquid 4-6.5 parts, keratin amino acid liquid 3-5 parts, collagen amino acid 3-5 parts, saccharomycete polypeptide 3-5 parts, xanthan gum 4.2-4.6 parts and water 95-105 parts
The composition comprises, by weight, 97-102 parts of water, 25-35 parts of glycerol, 35-45 parts of sodium hyaluronate solution, 20-22 parts of azalea acid solution, 28-30 parts of ellagic acid solution, 4.1-4.2 parts of glabridin solution, 21-24 parts of taxifolin solution, 27-30 parts of mulberroside solution, 15-17 parts of raspberry extract solution, 5-6 parts of sodium carbonate solution, 4-5 parts of keratin amino acid solution, 4-5 parts of collagen amino acid, 4-5 parts of saccharomycete polypeptide, 0.01 part of ML 3290.005, 0.01 part of JNJ-102295700.005, 0.01 part of SRI-0113810.005-0.01 part of xanthan gum and 4.5-4.6 parts of xanthan gum.
The composition comprises, by weight, 100 parts of water, 30 parts of glycerol, 40 parts of sodium hyaluronate solution, 20 parts of azalea acid solution, 30 parts of ellagic acid solution, 4.1 parts of glabridin solution, 22 parts of taxifolin solution, 27 parts of mulberry bark glycoside solution, 16 parts of raspberry extract solution, 5 parts of sodium carbonate solution, 5 parts of keratin amino acid solution, 5 parts of collagen amino acid, 5 parts of saccharomycete polypeptide, ML 3290.01 parts, JNJ-102295700.01 parts, SRI-0113810.01 parts and 4.6 parts of xanthan gum.
The ML329 formula is as follows:
JNJ-10229570 has the following structural formula:
the structural formula of SRI-011381 is as follows
The composition is mixed with an auxiliary agent to obtain a white freckle-removing skin care preparation; wherein the preparation is water agent, emulsion, unguent or ointment.
The preparation can be prepared according to the existing mode, wherein the auxiliary agent can be ethanol, propylene glycol and the like when the preparation is a water agent.
The adjuvant can be ethanol, propylene glycol, 305 emulsifier, etc.
The adjuvant can be water, ethanol, propylene glycol, squalane, etc
A preparation method of a whitening and freckle-removing composition comprises the steps of mixing moisturizing and buffering substances, heating to 80-92 ℃ and uniformly mixing, uniformly mixing active substances according to the proportion, mixing the uniformly mixed mixture, and finally adding xanthan gum to obtain the whitening and freckle-removing composition.
Wherein the moisture-keeping substances are sodium hyaluronate solution, glycerol, keratin amino acid solution and collagen amino acid; the buffer substance is sodium carbonate solution.
Further, the following steps are carried out:
a. sequentially introducing 95-105 parts of water, 20-40 parts of glycerol, 30-50 parts of sodium hyaluronate solution, 3-5 parts of keratin amino acid solution, 3-5 parts of collagen amino acid and 3-5 parts of saccharomycete polypeptide into a heating container, and uniformly stirring to mix the components;
b. heating the mixed solution in the step a to 80-92 ℃;
c. introducing 18-23 parts of azalea acid solution, 26-32 parts of ellagic acid solution, 4-4.2 parts of glabridin solution, 20-25 parts of taxifolin solution, 25-32 parts of mulberroside solution, 14-18 parts of raspberry extract solution, 0.01-0.01 part of ML 3290.001, 0.01-0.01 part of JNJ-102295700.001 and 0.01 part of SRI-0113810.001 into the heated mixed solution in the step b in sequence, and fully stirring and uniformly mixing;
d. and c, adding 4.2-4.6 parts of xanthan gum, 4-6.5 parts of sodium carbonate solution and a proper amount of deionized water into the mixed solution in the step c to obtain a finished product.
When the whitening and freckle-removing composition is used, the part needing to be smeared is cleaned, and the whitening and freckle-removing composition is uniformly smeared on the part with the color spots or the affected part once in the morning and at night. The product can also be used as general skin care product, and has whitening and beautifying effects after being applied.
The whitening and freckle-removing composition is prepared by mixing ML329, JNJ-10229570, SRI-011381, azalea acid, ellagic acid, glabridin, taxifolin, mulberroside and a raspberry extract according to a certain proportion, so that the whitening and freckle-removing composition can inhibit the formation of melanin, reduce the deposition of the melanin, accelerate the renewal and metabolism of melanocytes, improve the cytoprotective ability and realize the whitening and freckle-removing effects;
among them, ML329 targets MITF (microphylla-associated transcription factor) gene expression, and suppresses proliferation of cells requiring MITF proliferation. MITF is the main molecule for melanocyte development, proliferation and maintenance. MITF promotes pigmentation by modulating various pigment-related factors such as tyrosinase, tyrosinase-related protein 1 gene (TYRP-1), DOPA isomerase/tyrosinase-related protein 2(DCT/TYRP-2), QNR-71, and the like. Meanwhile, the MITF can also participate in the cell differentiation, cell cycle and cell survival process of melanocytes.
JNJ-10229570 is an antagonist of the melanocortin 1 receptor (MC1R) and melanocortin 5 receptor (MC 5R). MC1R and MC5R are G protein-coupled receptors that play a key role in pigmentation in humans and mice. Alpha-melanocyte stimulating hormone (alpha-MSH) activates MC1R and MCR5 dimers in melanocytes to stimulate cAMP signaling and melanin production. The JNJ-10229570 can regulate melanin formation process by inhibiting MC1R and MC5R, and can achieve whitening effect.
SRI-011381 is an agonist of transforming growth factor-beta 1 (TGF-beta 1), TGF-beta 1 can obviously inhibit the synthesis of melanin in a concentration-dependent mode and reduce the activity of tyrosinase which is a rate-limiting melanogenesis enzyme, and SRI-011381 can activate TGF-beta 1 to achieve the effect of reducing the synthesis of melanin.
The azelaic acid can be used as a melanin transport blocker to reduce the amount of transfer of melanocytes to keratinocytes.
Ellagic acid can react with free radicals, and has inhibitory effect on peroxidation of lipid in mitochondria and microsome. The process of forming melanin is that tyrosine is used as a substrate and is sequentially converted into dopa and dopaquinone under the action of tyrosinase, and finally, the melanin is formed. Ellagic acid has high affinity for ketones at the active site of tyrosinase, and can inhibit the activity of tyrosinase.
Glabridin (Glabridin) is an isoflavan classified from Glycyrrhiza glabra, and the number of DOPA-positive melanocytes was reduced on skin treated with Glabridin. Treatment with glabridin also reduced skin color due to the inhibition of melanogenesis.
The taxifolin is also called dihydroquercetin, dihydroquercetin or (2R, 3R) dihydroquercetin, and has obvious inhibition effect on tyrosinase.
Mulberroside is a stilbene compound, and the stilbene compound has good effects of resisting oxidation and inhibiting tyrosinase activity.
The extract of Rubi fructus can be used for treating pigmentation spot on skin, and has the effects of inhibiting melanin production process, thereby reducing melanin production. It regulates the inhibition of melanin production following transcription by tyrosinase gene expression, which can lead to down-regulation of cellular tyrosinase activity and a decrease in the amount of tyrosinase protein, which helps to reduce melanin synthesis in the skin, thereby alleviating black spots.
The invention has the beneficial effects that:
the whitening and freckle-removing composition is mainly used for inhibiting melanin formation, reducing pigmentation, accelerating melanocyte renewal and metabolism and improving cell protection capability. The whitening and freckle-removing composition can ensure that the skin is healthy, clear and whitened, and active ingredients in the whitening and freckle-removing composition can fully permeate into the epidermal layer with the help of the penetration enhancer, enter a skin circulatory system and are fully absorbed by cells, so that the whitening and freckle-removing composition plays a role in cleaning the skin. The JNJ-10229570 of the whitening and freckle-removing composition can inhibit the formation of melanin and reduce pigmentation; the azalea acid in the product of the invention blocks the transportation process of melanin and inhibits the expression of the melanin; ML329 and glabridin in the product can inhibit the proliferation and development of melanocyte and reduce the generation of melanin; SRI-011381, ellagic acid, taxifolin, mulberroside, and Rubi fructus extract can inhibit the activity of tyrosinase, and can regulate the expression of tyrosinase to reduce melanin synthesis.
Meanwhile, the collagen amino acid in the whitening and freckle-removing composition contains glycine, proline and hydroxyproline, so that raw materials are provided for supplementing collagen, and the skin environment is kept moist; the keratin amino acid in the whitening and freckle-removing composition has the functions of improving cell membranes and stabilizing biomacromolecules and enzyme activity. Has anti-irritant and anti-allergic effects. Can protect the skin against mechanical and chemical damage; the saccharomycete polypeptide in the whitening and freckle-removing composition has multiple effects of resisting oxidation, activating skin cell activity, stimulating fibroblasts to synthesize collagen and the like. The yeast polypeptide can also inhibit the activity of tyrosinase, thereby inhibiting the formation of melanin, and whitening and brightening the skin. The glycerol and the sodium hyaluronate solution in the whitening and freckle removing composition also have the moisturizing effect, so that the skin is whitened and the moisture is supplemented to achieve the healthy and transparent effect.
The whitening and freckle-removing composition can penetrate a barrier of a hydrophobic structure consisting of a cuticle and cuticle cells, can be fully absorbed by the cells, and avoids blocking pores. The whitening and freckle-removing composition disclosed by the invention comprises the following components in a synergistic effect: binding to the neuraminidase, inhibiting the enzymatic activity; reducing tyrosinase gene expression; antagonize alpha-MSH polypeptide and reduce the proliferation of melanocyte.
Drawings
FIG. 1 is a graph of relative gray scale of the tail of a mouse using the components of each sample sequence provided in example 1 of the present invention;
FIG. 2 is an example of a photograph of a corresponding mouse tail using the sequence components of each sample provided in example 1 of the present invention.
Detailed Description
The embodiments of the present invention will be further described with reference to the accompanying drawings and specific examples, it should be noted that the embodiments described herein are only for the purpose of illustrating and explaining the present invention and are not limited to the present invention.
The following compositions are commercially available and some of them can be obtained by solvent extraction of the starting material in a conventional manner, for example, the azelaic acid solution can be obtained by solvent extraction of the starting material rhododendron.
The implementation case is as follows:
the products used in the following examples were prepared as follows:
adding the components recorded in each sample in the table 1 to respectively obtain samples containing different specific components, firstly, uniformly mixing the auxiliary substances, uniformly mixing the active component substances, mixing the uniformly mixed mixtures, and finally, adding the regulating agent type substances to obtain the samples containing different components and different addition amounts.
a. Sequentially introducing water, glycerol, a sodium hyaluronate solution, a collagen amino acid solution, a keratin amino acid solution and saccharomycete polypeptide in the auxiliary agents into a heating container according to the proportion in the table 1, and uniformly stirring to mix the materials; b. heating the mixed solution in the step a to 80-92 ℃; c. b, sequentially introducing azalea acid liquid, ellagic acid liquid, glabridin liquid, taxifolin liquid, mulberroside liquid, raspberry extract liquid, ML329, JNJ-10229570 and SRI-011381 in the effective component substances into the heated mixed solution in the step b according to the proportion of each sample sequence in the table 1, and stirring and mixing; d. and d, adding xanthan gum and a proper amount of deionized water into the mixed solution in the step c to obtain a finished product.
Table 1 below shows the mixture of each component in parts by mass of each sample, and the gray scale values of each component were measured using imagej (see fig. 1), and data obtained by taking the average gray scale ratio (tail (upper gray scale/lower gray scale) × 100% was used as the whitening effect index, and the smaller the value, the better the whitening effect was.
Table 1: composition and whitening effect of each sample sequence in 11 sample sequences
The sample sequence 1 is a sample without the whitening effective component added, and the sample sequences 2 to 10 are samples obtained by sequentially adding a certain effective component less. The optimal ratio of each component in the sample sequence 11. It can be seen from fig. 1 and table 1 that the whitening effect of the samples in sample series 11 is most significant.
The prepared sample products are used for the tail of a mouse, the experimental method is to collect the wild mouse and carry out tail unhairing treatment, the upper end of the tail is used as an experimental group, the whitening products in the sample sequences are smeared, the lower end of the tail is not treated and is used as a control group, and ultraviolet irradiation is carried out for ten minutes every other day. After two weeks of the experiment, the degree of lightening of tail pigment spots was photographed and compared. Data obtained by taking the average gray ratio (tail (upper gray/lower gray) × 100%) as the whitening effect index shows that the smaller the value, the better the whitening effect.
As is apparent from the data in table 1, the sample sequences 2 to 11 all have whitening effects, while the mice of the sample sequence 1 have no whitening effect at all; meanwhile, the effects are different in the matching of different sample components, wherein the sequence 11 is the optimal proportion of each effective component of the product, namely the effective components are mixed and matched according to a certain proportion, so that the melanin inhibitor can inhibit the formation of melanin, reduce the deposition of the melanin, accelerate the renewal and metabolism of melanocytes, improve the cytoprotective ability, further ensure the best whitening effect of mice and realize the whitening and freckle removing effects; therefore, the active ingredients in the invention have effects in whitening and freckle removing products, and are all indispensable.
Finally, it should be noted that the above-mentioned contents are only used for illustrating the technical solutions of the present invention, and not for limiting the protection scope of the present invention, and that the simple modifications or equivalent substitutions of the technical solutions of the present invention by those of ordinary skill in the art can be made without departing from the spirit and scope of the technical solutions of the present invention.
Claims (7)
1. A whitening and freckle removing composition is characterized in that: the composition comprises, by weight, 3290.001-0.01 part of ML, JNJ-102295700.001-0.01 part of JNJ-102295700.001, 26-0.01 part of SRI-0113810.001, 20-40 parts of glycerol, 30-50 parts of sodium hyaluronate solution, 18-23 parts of azalea acid solution, 26-32 parts of ellagic acid solution, 4-4.2 parts of glabridin solution, 20-25 parts of taxifolin solution, 25-32 parts of mulberroside solution, 14-18 parts of raspberry extract solution, 4-6.5 parts of sodium carbonate solution, 3-5 parts of keratin amino acid solution, 3-5 parts of collagen amino acid, 3-5 parts of saccharomycete polypeptide, 4.2-4.6 parts of xanthan gum and 95-105 parts of water.
2. The whitening spot-removing composition according to claim 1, wherein: the composition comprises, by weight, 97-102 parts of water, 25-35 parts of glycerol, 35-45 parts of sodium hyaluronate solution, 20-22 parts of azalea acid solution, 28-30 parts of ellagic acid solution, 4.1-4.2 parts of glabridin solution, 21-24 parts of taxifolin solution, 27-30 parts of mulberroside solution, 15-17 parts of raspberry extract solution, 5-6 parts of sodium carbonate solution, 4-5 parts of keratin amino acid solution, 4-5 parts of collagen amino acid, 4-5 parts of saccharomycete polypeptide, 0.01 part of ML 3290.005, 0.01 part of JNJ-102295700.005, 0.01 part of SRI-0113810.005-0.01 part of xanthan gum and 4.5-4.6 parts of xanthan gum.
3. The whitening spot-removing composition according to claim 2, wherein: the composition comprises, by weight, 100 parts of water, 30 parts of glycerol, 40 parts of sodium hyaluronate solution, 20 parts of azalea acid solution, 30 parts of ellagic acid solution, 4.1 parts of glabridin solution, 22 parts of taxifolin solution, 27 parts of mulberry bark glycoside solution, 16 parts of raspberry extract solution, 5 parts of sodium carbonate solution, 5 parts of keratin amino acid solution, 5 parts of collagen amino acid, 5 parts of saccharomycete polypeptide, ML 3290.01 parts, JNJ-102295700.01 parts, SRI-0113810.01 parts and 4.6 parts of xanthan gum.
4. The whitening spot-removing composition according to any one of claims 1 to 3, wherein: the ML329 formula is as follows:
JNJ-10229570 has the following structural formula:
the structural formula of SRI-011381 is as follows
5. The whitening spot-removing composition according to any one of claims 1 to 3, wherein: the composition is used as an active ingredient and is mixed with an auxiliary agent to obtain the whitening and freckle-removing skin care preparation; wherein the preparation is water agent, emulsion, unguent or ointment.
6. The whitening spot-removing composition according to claim 5, wherein: the active component accounts for 0.1-99% of the mass of the preparation.
7. A method for preparing the whitening and freckle-removing composition according to claim 1, which is characterized by comprising the following steps: according to the weight parts of the whitening and freckle-removing composition, the moisturizing and buffering substances are mixed and heated to 80-92 ℃ to be uniformly mixed, other component substances are uniformly mixed, the two uniformly mixed mixtures are mixed, and finally xanthan gum is added to obtain the whitening and freckle-removing composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011100095.6A CN112168736A (en) | 2020-10-15 | 2020-10-15 | Whitening and freckle removing composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011100095.6A CN112168736A (en) | 2020-10-15 | 2020-10-15 | Whitening and freckle removing composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112168736A true CN112168736A (en) | 2021-01-05 |
Family
ID=73950383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011100095.6A Pending CN112168736A (en) | 2020-10-15 | 2020-10-15 | Whitening and freckle removing composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112168736A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114652629A (en) * | 2022-04-01 | 2022-06-24 | 淮安唯尔美化妆品有限公司 | Plant source component composition with tyrosinase inhibitory activity and application of plant source component composition in preparation of freckle-removing and whitening cosmetics |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670445A (en) * | 2012-05-23 | 2012-09-19 | 成都鹏翔生物科技有限公司 | Chinese medicinal face repair cream and preparation method thereof |
| US20160039756A1 (en) * | 2013-03-14 | 2016-02-11 | The Board of Trustees of the Leladn Stanford Junior University | Benzyl urea derivatives for activating tgf-beta signaling |
| US20160130222A1 (en) * | 2013-06-10 | 2016-05-12 | The General Hospital Corporation | Inhibitors of the mitf molecular pathway |
| CN108578270A (en) * | 2018-05-31 | 2018-09-28 | 苏州蔻美新材料有限公司 | A kind of preparation method of whitening mask |
| CN109662904A (en) * | 2019-02-14 | 2019-04-23 | 成都市葆姿健康管理有限公司 | It is a kind of to have effects that the skin care compositions of whitening antioxidation and its application and preparation method |
-
2020
- 2020-10-15 CN CN202011100095.6A patent/CN112168736A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670445A (en) * | 2012-05-23 | 2012-09-19 | 成都鹏翔生物科技有限公司 | Chinese medicinal face repair cream and preparation method thereof |
| US20160039756A1 (en) * | 2013-03-14 | 2016-02-11 | The Board of Trustees of the Leladn Stanford Junior University | Benzyl urea derivatives for activating tgf-beta signaling |
| US20160130222A1 (en) * | 2013-06-10 | 2016-05-12 | The General Hospital Corporation | Inhibitors of the mitf molecular pathway |
| CN108578270A (en) * | 2018-05-31 | 2018-09-28 | 苏州蔻美新材料有限公司 | A kind of preparation method of whitening mask |
| CN109662904A (en) * | 2019-02-14 | 2019-04-23 | 成都市葆姿健康管理有限公司 | It is a kind of to have effects that the skin care compositions of whitening antioxidation and its application and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| MAGDALENA EISINGER 等: "A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids", 《JOURNAL OF DERMATOLOGICAL SCIENCE》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114652629A (en) * | 2022-04-01 | 2022-06-24 | 淮安唯尔美化妆品有限公司 | Plant source component composition with tyrosinase inhibitory activity and application of plant source component composition in preparation of freckle-removing and whitening cosmetics |
| CN114652629B (en) * | 2022-04-01 | 2023-07-14 | 上海萧雅生物科技股份有限公司 | Plant source component composition with tyrosinase inhibitory activity and application thereof in preparing freckle-removing and whitening cosmetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1021161B1 (en) | Use of ellagic acid and its derivatives in cosmetics and dermatology | |
| CN109998938B (en) | Polypeptide composition for whitening, brightening and lightening spots | |
| CN107823095A (en) | A kind of active peptide facial mask | |
| CN113616566B (en) | Skin care essence for tightening skin and preparation method thereof | |
| CN108478501A (en) | A kind of surfactant and preparation method thereof with Whitening, spot and anti-oxidation function | |
| CN108703894A (en) | It is a kind of that there is whitening, anti-ageing complex polypeptide composition and preparation method thereof | |
| CN107531775B (en) | Collagen hydrolysate rich in collagen tripeptide and use of collagen hydrolysate | |
| KR20080065641A (en) | Use of compounds from centella asiatica | |
| KR20130017159A (en) | Composition for skin lightening comprising extract of ecklonia cava treated by enzyme | |
| CN110507582A (en) | A kind of anti-ageing remediation composition and its preparation method and application containing composite vegetables extractive | |
| CN114533644A (en) | Whitening composition, whitening and freckle-removing essence and preparation method thereof | |
| CN110279599A (en) | A kind of lightening compositions, suit containing lightening compositions and preparation method thereof | |
| CN114836488B (en) | Anti-wrinkle repair composition containing polypeptide and preparation method thereof | |
| CN1694716A (en) | Use of active extracts to lighten skin, lips, hair and/or nails | |
| CN112168736A (en) | Whitening and freckle removing composition and preparation method thereof | |
| KR101685579B1 (en) | Method for manufacturing skin-whitener composition containing Thuja orientalis and skin-whitener composition prepared therefrom | |
| KR20030024932A (en) | Cosmetic composition containing centella asiatica extracts | |
| KR20090064743A (en) | Composition of the skin external application or the food for accelerating proline recycling containing theanine | |
| CN111700836A (en) | Composition capable of improving skin color and whitening skin and skin care product containing composition | |
| CN109833276A (en) | A kind of whitening mask and preparation method thereof | |
| CN108653144B (en) | Whitening cosmetic | |
| CN113633585B (en) | External hair care composition and preparation with effects of preventing alopecia, promoting hair growth and blackening hair and preparation method thereof | |
| CN109745274B (en) | Tear-type traditional Chinese medicine whitening mask and preparation method thereof | |
| EP1429716B1 (en) | Cosmetic preparation with anti-wrinkle action | |
| KR101081424B1 (en) | External Skin Composition Containing Extract of Medicinal Plants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210105 |
|
| RJ01 | Rejection of invention patent application after publication |